Joinn Laboratories rose 2.54% to HK$24.18 as Hong Kong CXO and innovative-drug names rallied together; the stock spiked to HK$24.78 in the morning session, slid to HK$23.82 by 14:46 BJ time, then recovered into the close on 4.44 million shares worth about HK$108 million. WuXi AppTec and peers gained more than 10% intraday, pulling flows back into the sector. The Q3 2026 print backs the move: revenue of HK$566 million, up 63.77% year on year, net profit of HK$213 million, up 886.11%, and a 37.63% net margin, a clear step up from Q2's 7.19% revenue growth. CMB International lifted its target price to HK$30. Even so, the price sits below both MA20 of HK$24.61 and MA60 of HK$25.41, 25.78% under the 52-week high of HK$32.58, while up 21.14% year to date at 13.56x PE and 1.70x PB.